Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Helekal

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2026
Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling StudyMadeleine C Kline, Kirstin Oliveira Roster, David Helekal, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Zoliflodacin and gepotidacin cross-resistance in <i>Neisseria gonorrhoeae</i>Aditi Mukherjee, Sofia Op Blomqvist, David Helekal, et al.
Bioinformatics (Oxford, England)|September 27, 2023
Simulating structurally variable nuclear pore complexes for microscopyMaria Theiss, Jean-Karim Hériché, Craig Russell, et al.
The Journal of Infectious Diseases|March 20, 2026
Genetic background modulates zoliflodacin and gepotidacin cross-resistance and fitness in Neisseria gonorrhoeaeAditi Mukherjee, Sofia O P Blomqvist, David Helekal, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Fluoroquinolone resistance-conferring <i>gyrA</i> variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation <i>gyrB</i> <sup>D429N</sup> in <i>Neisseria gonorrhoeae</i>Aditi Mukherjee, Sofia Op Blomqvist, David Helekal, et al.
Plos Pathogens|May 11, 2026
Diversity and evolution of a phase-variable multi-locus antigen in Neisseria gonorrhoeaeQinQin Yu, Tatum D Mortimer, Sofia O P Blomqvist, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Diversity and evolution of a phase-variable multi-locus antigen in <i>Neisseria gonorrhoeae</i>QinQin Yu, Tatum D Mortimer, Sofia O P Blomqvist, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Quantifying the impact of antibiotic use and genetic determinants of resistance on bacterial lineage dynamicsDavid Helekal, Tatum D Mortimer, Aditi Mukherjee, et al.
Nature Microbiology|January 30, 2026
Quantifying the real-world impact of antibiotic use and genetic determinants of resistance on gonococcal dynamicsDavid Helekal, Tatum D Mortimer, Aditi Mukherjee, et al.
The Lancet. Infectious Diseases|May 10, 2026
Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational studyMatan Yechezkel, David Helekal, Banshri Kapadia, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2026
Comparing Strategies to Introduce Two New Antibiotics for Gonorrhea: A Modeling StudyMadeleine C Kline, Kirstin Oliveira Roster, David Helekal, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Zoliflodacin and gepotidacin cross-resistance in <i>Neisseria gonorrhoeae</i>Aditi Mukherjee, Sofia Op Blomqvist, David Helekal, et al.
Bioinformatics (Oxford, England)|September 27, 2023
Simulating structurally variable nuclear pore complexes for microscopyMaria Theiss, Jean-Karim Hériché, Craig Russell, et al.
The Journal of Infectious Diseases|March 20, 2026
Genetic background modulates zoliflodacin and gepotidacin cross-resistance and fitness in Neisseria gonorrhoeaeAditi Mukherjee, Sofia O P Blomqvist, David Helekal, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Fluoroquinolone resistance-conferring <i>gyrA</i> variants alter the fitness cost and potentiate the resistance of the zoliflodacin resistance mutation <i>gyrB</i> <sup>D429N</sup> in <i>Neisseria gonorrhoeae</i>Aditi Mukherjee, Sofia Op Blomqvist, David Helekal, et al.
Plos Pathogens|May 11, 2026
Diversity and evolution of a phase-variable multi-locus antigen in Neisseria gonorrhoeaeQinQin Yu, Tatum D Mortimer, Sofia O P Blomqvist, et al.
Biorxiv : the Preprint Server for Biology|February 12, 2026
Diversity and evolution of a phase-variable multi-locus antigen in <i>Neisseria gonorrhoeae</i>QinQin Yu, Tatum D Mortimer, Sofia O P Blomqvist, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
Quantifying the impact of antibiotic use and genetic determinants of resistance on bacterial lineage dynamicsDavid Helekal, Tatum D Mortimer, Aditi Mukherjee, et al.
Nature Microbiology|January 30, 2026
Quantifying the real-world impact of antibiotic use and genetic determinants of resistance on gonococcal dynamicsDavid Helekal, Tatum D Mortimer, Aditi Mukherjee, et al.
The Lancet. Infectious Diseases|May 10, 2026
Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational studyMatan Yechezkel, David Helekal, Banshri Kapadia, et al.
Pageof 2